MARKET WIREReuters • 1h ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
Why ZSTK Stock slipped -0.34% Today — RQD Quant Desk Flash
$2.93 -0.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.92
ZeroStack Corp. (ZSTK) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $63.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ZSTK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ZSTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, ZeroStack Corp. (NASDAQ: ZSTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $2.93 (-0.34% 1D, market cap $63.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZSTK ranks #949 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ZSTK compare to ESYN and COSM in the Health Care sector?
▼
Within the Health Care sector (Other Pharmaceuticals), ZSTK carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of 4.6%, and ROIC of -35.0%. By comparison, ESYN (EnerSyn Global Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $54.4M) and COSM (Cosmos Health Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, ZSTK leads on earnings multiple (N/A) while NUS leads on capital efficiency (6.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ZSTK?
▼
Per ZSTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790169), ZeroStack Corp. generated $35.7M in revenue (-0.5% YoY), $0 in net income, and -$8.8M in free cash flow against $130.2M in total assets and $50.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.92 (-0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (25/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-15% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZSTK)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (25/100 Composite)
🔍 WHY ZSTK SCORES 25/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (40% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (20% of score)
FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 30.3 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.37-11% Next Q
33
Q2 (-2Q)Grade E$3.89-19.5% Next Q
30
Q3 (-1Q)Grade E$3.13-6.4% Next Q
28
CurrentGrade E$2.93-10.7% Hist 90D α
25
Trajectory: E (33) → E (25)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ZSTK Turnaround Squeeze
While ZSTK currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.37) and Max Pain ($3.08) forces dealer call-delta covering toward $15.79.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZSTK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ZSTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ZSTK Stock slipped -0.34% Today — RQD Quant Desk Flash
ZeroStack Corp. (ZSTK) slipped -0.34% to $2.93, trading at 12% of its 52-week range ($1.32 – $15.04). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 12% of its 52-week range ($1.32 – $15.04) with RSI-14 at 30.3 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.93 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 4.6% gross margin and $0 annual free cash flow.
Live ZSTK Headlines & Catalysts
MARKET WIREReuters • 3h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 4h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 4h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 6h ago
Gold rises on softer oil; markets parse Fed signals - ReutersGold rises on softer oil; markets parse Fed signals Reuters
MARKET WIREReuters • 6h ago
China's Xi says Middle East should not become battleground for great power rivalry - ReutersChina's Xi says Middle East should not become battleground for great power rivalry Reuters
MARKET WIREReuters • 8h ago
Reliance earnings, lower oil prices power India's Sensex to near two-month high - ReutersReliance earnings, lower oil prices power India's Sensex to near two-month high Reuters
MARKET WIREReuters • 10h ago
Dollar pulls back ahead of US midterms; bitcoin stabilises after crypto heist - ReutersDollar pulls back ahead of US midterms; bitcoin stabilises after crypto heist Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZSTK)
- ✓Walkthrough of ZSTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ZSTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.05%📐 HORIZONTAL RANGE
2026-11-02O $2.94H $2.94L $2.93C $2.93VOL 79.4K
SUP: $-1.94SMA50: $4.37SMA200: $5.15
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ZSTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ZSTK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ZSTK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZSTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZSTK)
Health Care Rank #949 of 1016
⚔️ ESYN vs ZSTK Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ZSTK vs. ESYN, COSM, NUS, MEDS)
Industry: Other Pharmaceuticals (10 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ZeroStack Corp. (ZSTK) ranks #949 by composite RQD confidence (25/100, grade E) and #720 by equity capitalization ($63.9M). Within this direct 5-issuer industry benchmark cohort, ZSTK leads on earnings valuation at N/A trailing P/E, while NUS leads on capital efficiency and profitability with 6.7% ROIC and 69.4% gross margin. NUS currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with ZSTK at 25/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZSTK
ACTIVE
ZeroStack Corp. | E | 25/100 | — | 4.6% | -35.0% | -0.34% | $63.9M | Benchmark Subject |
| ESYN EnerSyn Global Inc. | D- | 40/100 | — | 53.0% | -35.0% | +3.10% | $54.4M | /esyn-vs-zstk → |
| COSM Cosmos Health Inc. | E | 29/100 | — | 12.1% | -35.0% | +11.45% | $27.9M | /cosm-vs-zstk → |
| NUS Nu Skin Enterprises Inc. | D+ | 53/100 | — | 69.4% | 6.7% | -1.47% | $228.3M | /nus-vs-zstk → |
| MEDS DataMeds AI Inc. | E | 28/100 | — | -27.5% | -35.0% | -7.73% | $9.8M | /meds-vs-zstk → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001790169In its most recent audited fiscal period (FY2025, filed 2025-12-31), ZeroStack Corp. (ZSTK) reported GAAP revenue of $35.7M (-0.5% vs. FY2024 revenue of $35.9M , and -53.1% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of -$8.7M, and free cash flow of -$8.8M (-70.4% YoY). On the balance sheet, ZSTK closed FY2025 with $130.2M in total assets against $50.8M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $35.7M | $0 | -$8.7M | -$8.8M | $130.2M | $50.8M |
| FY2024 (FY) | 2024-12-31 | $35.9M | -$15.9M | -$5.0M | -$5.2M | $26.2M | $0 |
| FY2023 (FY) | 2023-12-31 | $76.1M | -$57.0M | -$8.4M | -$8.4M | — | — |
3. ZSTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ZSTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, ZeroStack Corp. (NASDAQ: ZSTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $2.93 (-0.34% 1D, market cap $63.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZSTK ranks #949 in composite RQD confidence.
How does ZSTK compare to ESYN and COSM in the Health Care sector?
Within the Health Care sector (Other Pharmaceuticals), ZSTK carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of 4.6%, and ROIC of -35.0%. By comparison, ESYN (EnerSyn Global Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $54.4M) and COSM (Cosmos Health Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, ZSTK leads on earnings multiple (N/A) while NUS leads on capital efficiency (6.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ZSTK?
Per ZSTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790169), ZeroStack Corp. generated $35.7M in revenue (-0.5% YoY), $0 in net income, and -$8.8M in free cash flow against $130.2M in total assets and $50.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ZSTK trading relative to its 50-day, 200-day, and 52-week technical levels?
ZSTK last traded at $2.93 (-0.34% on volume of 79,396 shares), positioning the stock -32.95% below its 50-day simple moving average ($4.37) and -43.11% below its 200-day simple moving average ($5.15). Across its 52-week range of $1.32 to $15.04, ZSTK sits at the 11.7% percentile with a 14-day RSI of 30.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.56 to $3.30).
ZSTK Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ZSTK stock moving today?
Why ZSTK Stock slipped -0.34% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.